Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants

References

• Wu X, Yang Z-Y, Li Y, Hogerkorp C-M, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science. 2010;329(5993):856–10. doi:10.1126/science.1187659.
   PubMed Web of Science ®Google Scholar
• Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, Finzi A, Do Kwon Y, Scheid JF, Shi W, Xu L, et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science. 2010;329(5993):811–17. doi:10.1126/science.1192819.
   PubMed Web of Science ®Google Scholar
• Gilbert PB, Juraska M, deCamp AC, Karuna S, Edupuganti S, Mgodi N, Donnell DJ, Bentley C, Sista N, Andrew P, et al. Basis and statistical design of the passive HIV-1 Antibody Mediated Prevention (AMP) test-of-concept efficacy trials. Stat Commun Infect Dis. 2017;9. doi:10.1515/scid-2016-0001.
   PubMedGoogle Scholar
• Corey L, Gilbert PB, Juraska M, Montefiori DC, Morris L, Karuna ST, Edupuganti S, Mgodi NM, deCamp AC, Rudnicki E, et al. Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. N Engl J Med. 2021 Mar 18;384(11):1003–1014. doi:10.1056/NEJMoa2031738.PMID:33730454.
   Google Scholar
• Pegu A, Borate B, Huang Y, Pauthner MG, Hessell AJ, Julg B, Doria-Rose NA, Schmidt SD, Carpp LN, Cully MD, et al. A meta-analysis of passive immunization studies shows that serum-neutralizing antibody titer associates with protection against SHIV challenge. Cell Host Microbe. 2019;26:336–46 e3. doi:10.1016/j.chom.2019.08.014.
   PubMed Web of Science ®Google Scholar
• Huang Y, Zhang Y, Bailer R, Grunenberg N, Carpp LN, Seaton K, Mayer KH, Ledgerwood J, Corey L, Mascola J, et al. Brief report: prediction of serum HIV-1 neutralization titers after passive administration of VRC01. J Acquir Immune Defic Syndr. 2020;83:434–39. doi:10.1097/QAI.0000000000002272.
   PubMed Web of Science ®Google Scholar
• Mayer KH, Seaton KE, Huang Y, Grunenberg N, Isaacs A, Allen M, Ledgerwood JE, Frank I, Sobieszczyk ME, Baden LR, et al. Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: results of a phase 1 randomized trial. PLoS Med. 2017;14:e1002435. doi:10.1371/journal.pmed.1002435.
   PubMed Web of Science ®Google Scholar
• Shen L, Peterson S, Sedaghat AR, McMahon MA, Callender M, Zhang H, Zhou Y, Pitt E, Anderson KS, Acosta EP, et al. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med. 2008;14:762–66. doi:10.1038/nm1777.
   PubMed Web of Science ®Google Scholar
• Huang Y, Naidoo L, Zhang L, Carpp LN, Rudnicki E, Randhawa A, Gonzales P, McDermott A, Ledgerwood J, Lorenzo MMG, et al. Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials. EBioMedicine. 2021;64:103203. doi:10.1016/j.ebiom.2020.103203.
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, Coates EE, Yamshchikov G, Saunders JG, Holman L, Enama ME, DeZure A, Lynch RM, Gordon I, Plummer S, et al. Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. Clin Exp Immunol. 2015;182(3):289–301. doi:10.1111/cei.12692.
   PubMed Web of Science ®Google Scholar
• Sarzotti-Kelsoe M, Bailer RT, Turk E, Lin CL, Bilska M, Greene KM, Gao H, Todd CA, Ozaki DA, Seaman MS, et al. Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J Immunol Methods. 2014;409:131–46. doi:10.1016/j.jim.2013.11.022.
   PubMed Web of Science ®Google Scholar
• Montefiori DC. Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol Biol. 2009;485:395–405.
   PubMedGoogle Scholar
• deCamp A, Hraber P, Bailer RT, Seaman MS, Ochsenbauer C, Kappes J, Gottardo R, Edlefsen P, Self S, Tang H, et al. Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol. 2014;88(5):2489–507. doi:10.1128/JVI.02853-13.
   PubMed Web of Science ®Google Scholar
• Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharm. 2001;28(5):481–504. doi:10.1023/A:1012299115260.
   PubMed Web of Science ®Google Scholar
• Huang Y, Zhang L, Ledgerwood J, Grunenberg N, Bailer R, Isaacs A, Seaton K, Mayer KH, Capparelli E, Corey L, et al. Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults. MAbs. 2017;9(5):792–800. doi:10.1080/19420862.2017.1311435.
   PubMed Web of Science ®Google Scholar
• Monolix version 2019R1. Antony (France): Lixoft SAS; 2019 [accessed 2020 Nov]. http://lixoft.com/products/monolix/.
   Google Scholar
• R Core Team. R: a language and environment for statistical computing. Vienna (Austria): R Foundation for Statistical Computing; 2017 [accessed 2020 Nov]. https://www.R-project.org/.
   Google Scholar
• Carrasco JL, King TS, Chinchilli VM. The concordance correlation coefficient for repeated measures estimated by variance components. J Biopharm Stat. 2009;19(1):90–105. doi:10.1080/10543400802527890.
   PubMed Web of Science ®Google Scholar
• Carrasco JL, Phillips BR, Puig-Martinez J, King TS, Chinchilli VM. Estimation of the concordance correlation coefficient for repeated measures using SAS and R. Comput Methods Programs Biomed. 2013;109(3):293–304. doi:10.1016/j.cmpb.2012.09.002.
   PubMed Web of Science ®Google Scholar
• Miglietta R, Pastori C, Venuti A, Ochsenbauer C, Lopalco L. Synergy in monoclonal antibody neutralization of HIV-1 pseudoviruses and infectious molecular clones. J Transl Med. 2014;12(1):346. doi:10.1186/s12967-014-0346-3.
   PubMed Web of Science ®Google Scholar
• Berendam SJ, Styles TM, Morgan-Asiedu PK, Tenney D, Kumar A, Obregon-Perko V, Bar KJ, Saunders KO, Santra S, De Paris K, et al. Systematic assessment of antiviral potency, breadth, and synergy of triple broadly neutralizing antibody combinations against Simian-human immunodeficiency viruses. J Virol. 2020;95(3). doi:10.1128/JVI.01667-20.
   PubMed Web of Science ®Google Scholar
• Karuna ST, Corey L. Broadly neutralizing antibodies for HIV prevention. Annu Rev Med. 2020;71(1):329–46. doi:10.1146/annurev-med-110118-045506.
   PubMed Web of Science ®Google Scholar